2126 Stock Overview
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
JW (Cayman) Therapeutics Co. Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.80 |
| 52 Week High | HK$3.49 |
| 52 Week Low | HK$1.58 |
| Beta | 2.16 |
| 11 Month Change | -10.45% |
| 3 Month Change | 5.88% |
| 1 Year Change | -35.94% |
| 33 Year Change | -91.20% |
| 5 Year Change | n/a |
| Change since IPO | -91.82% |
Recent News & Updates
Shareholder Returns
| 2126 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.4% | -3.4% | -1.9% |
| 1Y | -35.9% | -38.2% | -6.7% |
Return vs Industry: 2126 matched the Hong Kong Biotechs industry which returned -36.4% over the past year.
Return vs Market: 2126 underperformed the Hong Kong Market which returned -5.5% over the past year.
Price Volatility
| 2126 volatility | |
|---|---|
| 2126 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2126's share price has been volatile over the past 3 months.
Volatility Over Time: 2126's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 398 | James Li | www.jwtherapeutics.com |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary
| 2126 fundamental statistics | |
|---|---|
| Market cap | HK$727.62m |
| Earnings (TTM) | -HK$826.71m |
| Revenue (TTM) | HK$187.15m |
3.9x
P/S Ratio-0.9x
P/E RatioIs 2126 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2126 income statement (TTM) | |
|---|---|
| Revenue | CN¥173.86m |
| Cost of Revenue | CN¥85.64m |
| Gross Profit | CN¥88.22m |
| Other Expenses | CN¥856.22m |
| Earnings | -CN¥768.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 50.74% |
| Net Profit Margin | -441.74% |
| Debt/Equity Ratio | 15.6% |
How did 2126 perform over the long term?
See historical performance and comparison